{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["IDH1-R132C inhibitor", "molecular docking", "molecular dynamics simulation", "tricarboxylic acid cycle (TCA cycle)", "virtual screening"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36160383", "DateRevised": {"Year": "2022", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "07"}], "Language": ["eng"], "ELocationID": ["982375", "10.3389/fphar.2022.982375"], "Journal": {"ISSN": "1663-9812", "JournalIssue": {"Volume": "13", "PubDate": {"Year": "2022"}}, "Title": "Frontiers in pharmacology", "ISOAbbreviation": "Front Pharmacol"}, "ArticleTitle": "Discovery of novel <i>IDH1</i>-R132C inhibitors through structure-based virtual screening.", "Pagination": {"StartPage": "982375", "MedlinePgn": "982375"}, "Abstract": {"AbstractText": ["Isocitrate dehydrogenase (<i>IDH</i>) belongs to a family of enzymes involved in glycometabolism. It is found in many living organisms and is one of the most mutated metabolic enzymes. In the current study, we identified novel <i>IDH</i>1-R132C inhibitors using docking-based virtual screening and cellular inhibition assays. A total of 100 molecules with high docking scores were obtained from docking-based virtual screening. The cellular inhibition assay demonstrated five compounds at a concentration of 10\u00a0\u03bcM could inhibit cancer cells harboring the <i>IDH</i>1-R132C mutation proliferation by > 50%. The compound (T001-0657) showed the most potent effect against cancer cells harboring the <i>IDH</i>1-R132C mutation with a half-maximal inhibitory concentration (IC<sub>50</sub>) value of 1.311\u00a0\u03bcM. It also showed a cytotoxic effect against cancer cells with wild-type <i>IDH</i>1 and normal cells with IC<sub>50</sub> values of 49.041\u00a0\u03bcM and >50\u00a0\u03bcM, respectively. Molecular dynamics simulations were performed to investigate the stability of the kinase structure binding of allosteric inhibitor compound A and the identified compound T001-0657 binds to <i>IDH</i>1-R132C. Root-mean-square deviation, root-mean-square fluctuation, and binding free energy calculations showed that both compounds bind tightly to <i>IDH</i>1-R132C. In conclusion, the compound identified in this study had high selectivity for cancer cells harboring <i>IDH</i>1-R132C mutation and could be considered a promising hit compound for further development of <i>IDH</i>1-R132C inhibitors."], "CopyrightInformation": "Copyright \u00a9 2022 Hu, Zeng, Ma, Yin, Zhao, Chen, Tang and Zuo."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R and D, Guiyang, China."}, {"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Precision Medicine Research Institute of Guizhou, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Hu", "ForeName": "Chujiao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Precision Medicine Research Institute of Guizhou, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Zeng", "ForeName": "Zhirui", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R and D, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Ma", "ForeName": "Dan", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Guizhou Medical University, Guiyang, China."}], "LastName": "Yin", "ForeName": "Zhixin", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Guizhou Medical University, Guiyang, China."}], "LastName": "Zhao", "ForeName": "Shanshan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Precision Medicine Research Institute of Guizhou, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Chen", "ForeName": "Tengxiang", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R and D, Guiyang, China."}], "LastName": "Tang", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Precision Medicine Research Institute of Guizhou, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Zuo", "ForeName": "Shi", "Initials": "S"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Pharmacol", "NlmUniqueID": "101548923", "ISSNLinking": "1663-9812"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "\nAbbas S., Lugthart S., Kavelaars F. G., Schelen A., Koenders J. E., Zeilemaker A., et al.  (2010). Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood\n116, 2122\u20132126. 10.1182/blood-2009-11-250878\nPubMed Abstract | 10.1182/blood-2009-11-250878 | Google Scholar\n", "ArticleIdList": ["10.1182/blood-2009-11-250878", "10.1182/blood-2009-11-250878", "20538800"]}, {"Citation": "\nAlhossary A., Handoko S. D., Mu Y., Kwoh C. K. (2015). Fast, accurate, and reliable molecular docking with QuickVina 2. Bioinformatics\n31, 2214\u20132216. 10.1093/bioinformatics/btv082\nPubMed Abstract | 10.1093/bioinformatics/btv082 | Google Scholar\n", "ArticleIdList": ["10.1093/bioinformatics/btv082", "10.1093/bioinformatics/btv082", "25717194"]}, {"Citation": "\nAmary M. F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., et al.  (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol.\n224, 334\u2013343. 10.1002/path.2913\nPubMed Abstract | 10.1002/path.2913 | Google Scholar\n", "ArticleIdList": ["10.1002/path.2913", "10.1002/path.2913", "21598255"]}, {"Citation": "\nAmatangelo M. D., Quek L., Shih A., Stein E. M., Roshal M., David M. D., et al.  (2017). Enasidenib induces acute myeloid leukemia cell differentiation to PromoteClinical response. Blood\n130, 732\u2013741. 10.1182/blood-2017-04-779447\nPubMed Abstract | 10.1182/blood-2017-04-779447 | Google Scholar\n", "ArticleIdList": ["10.1182/blood-2017-04-779447", "10.1182/blood-2017-04-779447", "PMC5553578", "28588019"]}, {"Citation": "\nBadur M. G., Muthusamy T., Parker S. J., Ma S., McBrayer S. K., Cordes T., et al.  (2018). Oncogenic R132 IDH1 mutations limit NADPH for de novo lipogenesis through (D)2-hydroxyglutarate production in fibrosarcoma sells. Cell Rep.\n25, 1018\u20131026. e4. 10.1016/j.celrep.2018.09.074\nPubMed Abstract | 10.1016/j.celrep.2018.09.074 | Google Scholar\n", "ArticleIdList": ["10.1016/j.celrep.2018.09.074", "10.1016/j.celrep.2018.09.074", "PMC6613636", "30355481"]}, {"Citation": "\nBajad N. G., Rayala S., Gutti G., Sharma A., Singh M., Kumar A., et al.  (2021). Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. Curr. Res. Pharmacol. Drug Discov.\n2, 100026. 10.1016/j.crphar.2021.100026\nPubMed Abstract | 10.1016/j.crphar.2021.100026 | Google Scholar\n", "ArticleIdList": ["10.1016/j.crphar.2021.100026", "10.1016/j.crphar.2021.100026", "PMC8120892", "34870145"]}, {"Citation": "\nBorger D. R., Tanabe K. K., Fan K. C., Lopez H. U., Fantin V. R., Straley K. S., et al.  (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist\n17, 72\u201379. 10.1634/theoncologist.2011-0386\nPubMed Abstract | 10.1634/theoncologist.2011-0386 | Google Scholar\n", "ArticleIdList": ["10.1634/theoncologist.2011-0386", "10.1634/theoncologist.2011-0386", "PMC3267826", "22180306"]}, {"Citation": "\nCase D. A., Cheatham T. E., 3rd, Darden T., Gohlke H., Luo R., Merz K. M., Jr, et al.  (2005). The Amber biomolecular simulation programs. J. Comput. Chem.\n26, 1668\u20131688. 10.1002/jcc.20290\nPubMed Abstract | 10.1002/jcc.20290 | Google Scholar\n", "ArticleIdList": ["10.1002/jcc.20290", "10.1002/jcc.20290", "PMC1989667", "16200636"]}, {"Citation": "\nChaturvedi A., Herbst L., Pusch S., Klett L., Goparaju R., Stichel D., et al.  (2017). Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo\n. Leukemia\n31, 2020\u20132028. 10.1038/leu.2017.46\nPubMed Abstract | 10.1038/leu.2017.46 | Google Scholar\n", "ArticleIdList": ["10.1038/leu.2017.46", "10.1038/leu.2017.46", "PMC5629366", "28232670"]}, {"Citation": "\nChoudhury C., Arul Murugan N., Priyakumar U. D. (2022). Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods. Drug Discov. Today\n27, 1847\u20131861. 10.1016/j.drudis.2022.03.006\nPubMed Abstract | 10.1016/j.drudis.2022.03.006 | Google Scholar\n", "ArticleIdList": ["10.1016/j.drudis.2022.03.006", "10.1016/j.drudis.2022.03.006", "PMC8920090", "35301148"]}, {"Citation": "\nDamato S., Alorjani M., Bonar F., McCarthy S. W., Cannon S. R., O\u2019Donnell P., et al.  (2012). \nIDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology\n60, 363\u2013365. 10.1111/j.1365-2559.2011.04010.x\nPubMed Abstract | 10.1111/j.1365-2559.2011.04010.x | Google Scholar\n", "ArticleIdList": ["10.1111/j.1365-2559.2011.04010.x", "10.1111/j.1365-2559.2011.04010.x", "22074484"]}, {"Citation": "\nDang L., Su S. M. (2017). Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: From basic discovery to therapeutics development. Annu. Rev. Biochem.\n86, 305\u2013331. 10.1146/annurev-biochem-061516-044732\nPubMed Abstract | 10.1146/annurev-biochem-061516-044732 | Google Scholar\n", "ArticleIdList": ["10.1146/annurev-biochem-061516-044732", "10.1146/annurev-biochem-061516-044732", "28375741"]}, {"Citation": "\nDang L., Yen K., Attar E. C. (2016). \nIDH mutations in cancer and progress toward development of targeted therapeutics. Ann. Oncol.\n27, 599\u2013608. 10.1093/annonc/mdw013\nPubMed Abstract | 10.1093/annonc/mdw013 | Google Scholar\n", "ArticleIdList": ["10.1093/annonc/mdw013", "10.1093/annonc/mdw013", "27005468"]}, {"Citation": "\nFalini B., Spinelli O., Meggendorfer M., Martelli M. P., Bigerna B., Ascani S., et al.  (2019). \nIDH1-R132 changes vary according to NPM1 and other mutations status in AML. Leukemia\n33, 1043\u20131047. 10.1038/s41375-018-0299-2\nPubMed Abstract | 10.1038/s41375-018-0299-2 | Google Scholar\n", "ArticleIdList": ["10.1038/s41375-018-0299-2", "10.1038/s41375-018-0299-2", "PMC6484707", "30622284"]}, {"Citation": "\nFerreira L. G., Dos Santos R. N., Oliva G., Andricopulo A. D. (2015). Molecular docking and structure-based drug design strategies. Molecules\n20, 13384\u201313421. 10.3390/molecules200713384\nPubMed Abstract | 10.3390/molecules200713384 | Google Scholar\n", "ArticleIdList": ["10.3390/molecules200713384", "10.3390/molecules200713384", "PMC6332083", "26205061"]}, {"Citation": "\nGohlke H., Case D. A. (2004). Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex ras-raf. J. Comput. Chem.\n25, 238\u2013250. 10.1002/jcc.10379\nPubMed Abstract | 10.1002/jcc.10379 | Google Scholar\n", "ArticleIdList": ["10.1002/jcc.10379", "10.1002/jcc.10379", "14648622"]}, {"Citation": "\nHeuser M., Palmisiano N., Mantzaris I., Mims A., DiNardo C., Silverman L. R., et al.  (2020). Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia\n34, 2903\u20132913. 10.1038/s41375-020-0996-5\nPubMed Abstract | 10.1038/s41375-020-0996-5 | Google Scholar\n", "ArticleIdList": ["10.1038/s41375-020-0996-5", "10.1038/s41375-020-0996-5", "PMC7584476", "32733012"]}, {"Citation": "\nHussain H., Green I. R., Abbas G., Adekenov S. M., Hussain W., Ali I. (2019). Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: Patent review (2015\u20132018). Expert Opin. Ther. Pat.\n29, 689\u2013702. 10.1080/13543776.2019.1655542\nPubMed Abstract | 10.1080/13543776.2019.1655542 | Google Scholar\n", "ArticleIdList": ["10.1080/13543776.2019.1655542", "10.1080/13543776.2019.1655542", "31402706"]}, {"Citation": "\nKhalid R. R., Maryam A., \u00c7\u0131naro\u011flu S. S., Siddiqi A. R., Sezerman O. U. (2022). A recursive molecular docking coupled with energy-based pose-rescoring and MD simulations to identify hsGC \u03b2H-NOX allosteric modulators for cardiovascular dysfunctions. J. Biomol. Struct. Dyn.\n40, 6128\u20136150. 10.1080/07391102.2021.1877818\nPubMed Abstract | 10.1080/07391102.2021.1877818 | Google Scholar\n", "ArticleIdList": ["10.1080/07391102.2021.1877818", "10.1080/07391102.2021.1877818", "33522438"]}, {"Citation": "\nKrogan N. J., Lippman S., Agard D. A., Ashworth A., Ideker T. (2015). The cancer cell map initiative: Defining the hallmark networks of cancer. Mol. Cell\n58, 690\u2013698. 10.1016/j.molcel.2015.05.008\nPubMed Abstract | 10.1016/j.molcel.2015.05.008 | Google Scholar\n", "ArticleIdList": ["10.1016/j.molcel.2015.05.008", "10.1016/j.molcel.2015.05.008", "PMC5359018", "26000852"]}, {"Citation": "\nKumari R., Rathi R., Pathak S. R., Dalal V. (2021). Computational investigation of potent inhibitors against YsxC: Structure-based pharmacophore modeling, molecular docking, molecular dynamics, and binding free energy. J. Biomol. Struct. Dyn.\n1, 1\u201312. 10.1080/07391102.2021.2015446\n10.1080/07391102.2021.2015446 | Google Scholar\n", "ArticleIdList": ["10.1080/07391102.2021.2015446", "10.1080/07391102.2021.2015446", "34913841"]}, {"Citation": "\nMachida Y., Nakagawa M., Matsunaga H., Yamaguchi M., Ogawara Y., Shima Y., et al.  (2020). A potent blood-brain barrier-permeable mutant IDH1 inhibitor suppresses the growth of glioblastoma with IDH1 mutation in a patient-derived orthotopic xenograft model. Mol. Cancer Ther.\n19, 375\u2013383. 10.1158/1535-7163.MCT-18-1349\nPubMed Abstract | 10.1158/1535-7163.MCT-18-1349 | Google Scholar\n", "ArticleIdList": ["10.1158/1535-7163.MCT-18-1349", "10.1158/1535-7163.MCT-18-1349", "31727689"]}, {"Citation": "\nMaier J. A., Martinez C., Kasavajhala K., Wickstrom L., Hauser K. E., Simmerling C. (2015). ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput.\n11, 3696\u20133713. 10.1021/acs.jctc.5b00255\nPubMed Abstract | 10.1021/acs.jctc.5b00255 | Google Scholar\n", "ArticleIdList": ["10.1021/acs.jctc.5b00255", "10.1021/acs.jctc.5b00255", "PMC4821407", "26574453"]}, {"Citation": "\nMartelli M. P., Martino G., Cardinali V., Falini B., Martinelli G., Cerchione C. (2020). Enasidenib and ivosidenib in AML. Minerva Med.\n111 (5), 411\u2013426. 10.23736/S0026-4806.20.07024-X\nPubMed Abstract | 10.23736/S0026-4806.20.07024-X | Google Scholar\n", "ArticleIdList": ["10.23736/S0026-4806.20.07024-X", "10.23736/S0026-4806.20.07024-X", "32955829"]}, {"Citation": "\nMiller B. R., 3rd, McGee T. D., Jr, Swails J. M., Homeyer N., Gohlke H., Roitberg A. E. (2012). MMPBSA.py: An efficient program for end-state free energy calculations. J. Chem. Theory Comput.\n8, 3314\u20133321. 10.1021/ct300418h\nPubMed Abstract | 10.1021/ct300418h | Google Scholar\n", "ArticleIdList": ["10.1021/ct300418h", "10.1021/ct300418h", "26605738"]}, {"Citation": "\nMondesir J., Willekens C., Touat M., de Botton S. (2016). \nIDH1 and IDH2 mutations as novel therapeutic targets: Current perspectives. J. Blood Med.\n7, 171\u2013180. 10.2147/JBM.S70716\nPubMed Abstract | 10.2147/JBM.S70716 | Google Scholar\n", "ArticleIdList": ["10.2147/JBM.S70716", "10.2147/JBM.S70716", "PMC5015873", "27621679"]}, {"Citation": "\nMorris G. M., Huey R., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S., et al.  (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem.\n30, 2785\u20132791. 10.1002/jcc.21256\nPubMed Abstract | 10.1002/jcc.21256 | Google Scholar\n", "ArticleIdList": ["10.1002/jcc.21256", "10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "\nNayar D., Agarwal M., Chakravarty C. (2011). Comparison of tetrahedral order, liquid state anomalies, and hydration behavior of mTIP3P and TIP4P water models. J. Chem. Theory Comput.\n7, 3354\u20133367. 10.1021/ct2002732\nPubMed Abstract | 10.1021/ct2002732 | Google Scholar\n", "ArticleIdList": ["10.1021/ct2002732", "10.1021/ct2002732", "26598167"]}, {"Citation": "\nO\u2019Boyle N. M., Banck M., James C. A., Morley C., Vandermeersch T., Hutchison G. R. (2011). Open babel: An open chemical toolbox. J. Cheminform.\n3, 33. 10.1186/1758-2946-3-33\nPubMed Abstract | 10.1186/1758-2946-3-33 | Google Scholar\n", "ArticleIdList": ["10.1186/1758-2946-3-33", "10.1186/1758-2946-3-33", "PMC3198950", "21982300"]}, {"Citation": "\nPapaemmanuil E., Gerstung M., Bullinger L., Gaidzik V. I., Paschka P., Roberts N. D., et al.  (2016). Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med.\n374, 2209\u20132221. 10.1056/NEJMoa1516192\nPubMed Abstract | 10.1056/NEJMoa1516192 | Google Scholar\n", "ArticleIdList": ["10.1056/NEJMoa1516192", "10.1056/NEJMoa1516192", "PMC4979995", "27276561"]}, {"Citation": "\nParsons D. W., Jones S., Zhang X., Lin J. C., Leary R. J., Angenendt P., et al.  (2008). An integrated genomic analysis of human glioblastoma multiforme. Science\n321, 1807\u20131812. 10.1126/science.1164382\nPubMed Abstract | 10.1126/science.1164382 | Google Scholar\n", "ArticleIdList": ["10.1126/science.1164382", "10.1126/science.1164382", "PMC2820389", "18772396"]}, {"Citation": "\nPopovici-Muller J., Lemieux R. M., Artin E., Saunders J. O., Salituro F. G., Travins J., et al.  (2018). Discovery of AG-120 (ivosidenib): A first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med. Chem. Lett.\n9, 300\u2013305. 10.1021/acsmedchemlett.7b00421\nPubMed Abstract | 10.1021/acsmedchemlett.7b00421 | Google Scholar\n", "ArticleIdList": ["10.1021/acsmedchemlett.7b00421", "10.1021/acsmedchemlett.7b00421", "PMC5900343", "29670690"]}, {"Citation": "\nPusch S., Krausert S., Fischer V., Balss J., Ott M., Schrimpf D., et al.  (2017). Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo\n. Acta Neuropathol.\n133, 629\u2013644. 10.1007/s00401-017-1677-y\nPubMed Abstract | 10.1007/s00401-017-1677-y | Google Scholar\n", "ArticleIdList": ["10.1007/s00401-017-1677-y", "10.1007/s00401-017-1677-y", "28124097"]}, {"Citation": "\nReitman Z. J., Yan H. (2010). Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst.\n102, 932\u2013941. 10.1093/jnci/djq187\nPubMed Abstract | 10.1093/jnci/djq187 | Google Scholar\n", "ArticleIdList": ["10.1093/jnci/djq187", "10.1093/jnci/djq187", "PMC2897878", "20513808"]}, {"Citation": "\nSantos R., Ursu O., Gaulton A., Bento A. P., Donadi R. S., Bologa C. G., et al.  (2017). A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov.\n16, 19\u201334. 10.1038/nrd.2016.230\nPubMed Abstract | 10.1038/nrd.2016.230 | Google Scholar\n", "ArticleIdList": ["10.1038/nrd.2016.230", "10.1038/nrd.2016.230", "PMC6314433", "27910877"]}, {"Citation": "\n\u015aled\u017a P., Caflisch A. (2018). Protein structure-based drug design: From docking to molecular dynamics. Curr. Opin. Struct. Biol.\n48, 93\u2013102. 10.1016/j.sbi.2017.10.010\nPubMed Abstract | 10.1016/j.sbi.2017.10.010 | Google Scholar\n", "ArticleIdList": ["10.1016/j.sbi.2017.10.010", "10.1016/j.sbi.2017.10.010", "29149726"]}, {"Citation": "\nWard P. S., Patel J., Wise D. R., Abdel-Wahab O., Bennett B. D., Coller H. A., et al.  (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate. Cancer Cell\n17, 225\u2013234. 10.1016/j.ccr.2010.01.020\nPubMed Abstract | 10.1016/j.ccr.2010.01.020 | Google Scholar\n", "ArticleIdList": ["10.1016/j.ccr.2010.01.020", "10.1016/j.ccr.2010.01.020", "PMC2849316", "20171147"]}, {"Citation": "\nXu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., et al.  (2004). Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem.\n279, 33946\u201333957. 10.1074/jbc.M404298200\nPubMed Abstract | 10.1074/jbc.M404298200 | Google Scholar\n", "ArticleIdList": ["10.1074/jbc.M404298200", "10.1074/jbc.M404298200", "15173171"]}, {"Citation": "\nYan H., Parsons D. W., Jin G., McLendon R., Rasheed B. A., Yuan W., et al.  (2009). \nIDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.\n360, 765\u2013773. 10.1056/NEJMoa0808710\nPubMed Abstract | 10.1056/NEJMoa0808710 | Google Scholar\n", "ArticleIdList": ["10.1056/NEJMoa0808710", "10.1056/NEJMoa0808710", "PMC2820383", "19228619"]}, {"Citation": "\nYang B., Zhong C., Peng Y., Lai Z., Ding J. (2010). Molecular mechanisms of \u201coff-on switch\u201d of activities of human IDH1 by tumor-associated mutation R132H. Cell Res.\n20, 1188\u20131200. 10.1038/cr.2010.145\nPubMed Abstract | 10.1038/cr.2010.145 | Google Scholar\n", "ArticleIdList": ["10.1038/cr.2010.145", "10.1038/cr.2010.145", "20975740"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "30"}, {"Year": "2022", "Month": "8", "Day": "16"}, {"Year": "2022", "Month": "9", "Day": "26", "Hour": "17", "Minute": "50"}, {"Year": "2022", "Month": "9", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "27", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "9", "Day": "7"}], "PublicationStatus": "epublish", "ArticleIdList": ["36160383", "PMC9491111", "10.3389/fphar.2022.982375", "982375"]}}], "PubmedBookArticle": []}